 Patients will be treated with radiotherapy with 50Gy22fx6 weeks, plus hyperthermia for 40 minutes within 2hr after irradiation, with maximum temperature setted on 42C 0.5C as upper limit, once a week since the 1st week of radiation for a total of 6 times. The regimen of concurrent chemotherapy will be cisplatin 20mgm2 and taxotere 10-12mgm2 per week for 6 weekly cycles on the day before radiotherapy and hyperthermia treatment. The two chemotherapy agents will be given in only one day every week, according to the weekly dose. According to Gehan two-stage design, provided the estimated tumor response rate using this regimen is about 40 and objective tumor response is observed in 1 of the first 6 patients enrolled, α0.05 will be achieved indicating a preliminary efficacy. Then the Gehan second stage will be started. With a set of 5 precision and an assumption of 10 dropout rate, 39 additional patients will be enrolled in the Gehan second stage depending on the actual number with tumor response in the Gehan first stage totaling 45 patients when counting the first 6 in the Gehan first stage. The tumor response, adverse effects and various survival curves will be analyzed. 